AbbVie (ABBV) Finished Goods (2012 - 2016)
AbbVie (ABBV) reported Finished Goods of $556.0 million for Q2 2016, up 16.32% year-over-year from $478.0 million in Q3 2015, and up 0.72% quarter-over-quarter from $552.0 million in Q1 2016.
AbbVie (ABBV) Finished Goods (2012 - 2016) Analysis & Trends
AbbVie (ABBV) has 5 years of Finished Goods data on file, last reported at $556.0 million in Q2 2016.
- Finished Goods for Q2 2016 came in at $556.0 million, up 16.32% year-over-year; the trailing twelve-month figure through Jun 2016 was $556.0 million (up 16.32% YoY), and the FY2015 annual result was $469.0 million, up 37.54% from the prior year.
- Finished Goods grew to $556.0 million in Q2 2016 per ABBV's latest filing, from $552.0 million in the prior quarter.
- Over five years, Finished Goods peaked at $640.0 million in Q3 2015 and troughed at $280.0 million in Q3 2014.
- A 5-year average of $479.5 million and a median of $485.0 million in 2013 frame the typical range for Finished Goods.
- The sharpest annual moves came in 2014 and 2015: Finished Goods plunged 41.42% in 2014, then jumped 128.57% in 2015.
- A 5-year view of Finished Goods shows it stood at $547.0 million in 2012, then dropped by 11.33% to $485.0 million in 2013, then decreased by 29.69% to $341.0 million in 2014, then soared by 37.54% to $469.0 million in 2015, then rose by 18.55% to $556.0 million in 2016.
- Business Quant data shows ABBV's Finished Goods at $556.0 million in Q2 2016, $552.0 million in Q1 2016, and $469.0 million in Q4 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 556.00 Mn |
| Mar 31, 2016 | 552.00 Mn |
| Dec 31, 2015 | 469.00 Mn |
| Sep 30, 2015 | 640.00 Mn |
| Jun 30, 2015 | 478.00 Mn |
| Mar 31, 2015 | 291.00 Mn |
| Dec 31, 2014 | 341.00 Mn |
| Sep 30, 2014 | 280.00 Mn |
| Dec 31, 2013 | 485.00 Mn |
| Sep 30, 2013 | 478.00 Mn |
| Jun 30, 2013 | 504.00 Mn |
| Mar 31, 2013 | 613.00 Mn |
| Dec 31, 2012 | 547.00 Mn |